CRDF Q3 2021 Earnings — Cardiff Oncology, Inc. Revenue & Financial Results | Market Cap Arena

CRDFCardiff Oncology, Inc.

$133M

Q3 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$86,000-36.8% YoY

Gross Profit

$86,000100.0% margin

Operating Income

-$7M-8137.2% margin

Net Income

-$7M-8038.4% margin

EPS (Diluted)

$-0.17

QoQ Revenue Growth

+26.5%

Cash Flow

Operating Cash Flow

-$5M

Free Cash Flow

-$6M

Stock-Based Comp.

$940,000

Balance Sheet

Total Assets

$141M

Total Liabilities

$8M

Stockholders' Equity

$134M

Cash & Equivalents

$13M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$86,000	$136,000	-36.8%
Gross Profit	$86,000	$136,000	-36.8%
Operating Income	-$7M	-$4M	-60.4%
Net Income	-$7M	-$4M	-53.7%